Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
10 oct. 2024 16h05 HE
|
Sutro Biopharma, Inc.
Proprietary cell-free platform enables the design of next-generation ADCs intended to broaden addressable patient populations STRO-004 (tissue factor ADC) preclinical data has demonstrated greater...
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
20 sept. 2024 16h01 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
14 sept. 2024 03h00 HE
|
Sutro Biopharma, Inc.
- 4.3 mg/kg of luveltamab tazevibulin (luvelta) in combination with standard dose of bevacizumab (15 mg/kg) every 3 weeks resulted in a 56% objective response rate in patients with late-stage ovarian...
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024
11 sept. 2024 08h00 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
22 août 2024 08h00 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
13 août 2024 16h30 HE
|
Sutro Biopharma, Inc.
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the...
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
09 juil. 2024 08h00 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
13 mai 2024 16h30 HE
|
Sutro Biopharma, Inc.
- Investigational New Drug application for non-small cell lung cancer trial with luvelta cleared by U.S. Food and Drug Administration; Phase 2 on track to begin dosing in the second half of 2024 - ...
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
30 avr. 2024 08h00 HE
|
Sutro Biopharma, Inc.
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization...
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
02 avr. 2024 06h18 HE
|
Sutro Biopharma, Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...